Akebia Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
AKBA Nasdaq 2836 www.akebia.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Akebia Therapeutics, Inc.

Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference - Mar 3rd, 2026 6:00 am
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Mar 2nd, 2026 2:05 pm
Akebia Therapeutics, Inc. Q4 2025 Earnings Call Summary - Feb 27th, 2026 6:30 am
Akebia Therapeutics Inc (AKBA) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amidst ... - Feb 26th, 2026 2:14 pm
Akebia (AKBA) Q4 2025 Earnings Call Transcript - Feb 26th, 2026 12:25 pm
Akebia Therapeutics Q4 Earnings Call Highlights - Feb 26th, 2026 7:16 am
Akebia Therapeutics: Q4 Earnings Snapshot - Feb 26th, 2026 5:30 am
Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights - Feb 26th, 2026 5:00 am
Piper Sandler Lowers Akebia Therapeutics (AKBA) PT to $4 as Firm Updates Estimates Following Year-End Reports - Feb 19th, 2026 5:28 pm
Ardelyx (ARDX) Reports Break-Even Earnings for Q4 - Feb 19th, 2026 3:10 pm
Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights - Feb 19th, 2026 6:00 am
Akebia Therapeutics Spotlights VAFSEO Dialysis Push, TIW Dosing Plan and Rare Kidney Pipeline at Summit - Feb 12th, 2026 8:34 am
Why The Narrative Around Akebia Therapeutics (AKBA) Is Shifting After New Valuation Reset - Feb 7th, 2026 2:05 pm
Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - Feb 4th, 2026 6:00 am
Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook - Jan 12th, 2026 6:00 am
Akebia announces first patient dosed in Phase 2 trial of praliciguat - Jan 7th, 2026 6:22 am
Akebia Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Praliciguat for the Treatment of Focal Segmental Glomerulosclerosis (FSGS) - Jan 6th, 2026 6:00 am
Akebia Therapeutics Expands Portfolio Beyond Anemia with New Rare Kidney Disease Pipeline Centered on AKB-097 and Praliciguat - Dec 28th, 2025 10:46 am
Analysts Are Optimistic We'll See A Profit From Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Dec 11th, 2025 4:14 am
This Penny Biotech Stock Just Doubled on a Key Acquisition. Should You Buy Shares Here? - Dec 2nd, 2025 9:28 am